Evidence map›Paper›PMID 31385226›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2020

Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registry.

A Viúdez, A Carmona-Bayonas, J Gallego, A Lacalle, R Hernández, J M Cano, I Macías, A Custodio, E Martínez de Castro, A Sánchez and 18 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

A ViúdezMedical Oncology Department, Complejo Hospitalario de Navarra (CHN), OncobionaTras Unit, Navarrabiomed, Navarrabiomed Biomedical Center, IdiSNA, Irunlarrea 3, 31008, Pamplona, Navarra, Spain. aviudez@outlook.es.ORCID http://orcid.org/0000-0001-8810-6851
A Carmona-BayonasHematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, University of Murcia, IMIB, Murcia, Spain.
J GallegoMedical Oncology Department, Hospital Universitario de Elche, Elche, Spain.
A LacalleMedical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain.
R HernándezMedical Oncology Department, Hospital Universitario de Canarias, Tenerife, Spain.
J M CanoMedical Oncology Department, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain.
I MacíasMedical Oncology Department, Hospital Universitario Parc Tauli, Sabadell, Spain.
A CustodioMedical Oncology Department, Hospital Universitario La Paz, Madrid, Spain.
E Martínez de CastroMedical Oncology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
A SánchezMedical Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain.
L IglesiaMedical Oncology Department, Complejo Hospitalario de Orense, Orense, Spain.
P RegueraMedical Oncology Department, Hospital Universitario Ramón Y Cajal, Madrid, Spain.
L VisaMedical Oncology Department, Hospital Universitario El Mar, Barcelona, Spain.
A AzkarateMedical Oncology Department, Hospital Universitario Son Espases, Mallorca, Spain.
M Sánchez-CánovasHematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, Murcia, Spain.
M MangasMedical Oncology Department, Hospital Galdakao-Usansolo, Galdakao-Usansolo, Spain.
M L LimónMedical Oncology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
A Martínez-TorrónPharmacy Department, Hospital Universitario Central de Asturias, Oviedo, Spain.
E AsensioMedical Oncology Department, Hospital Universitario de Elche, Elche, Spain.
A RamchandaniMedical Oncology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain.
A Martín-CarniceroMedical Oncology Department, Complejo Hospitalario San Millán, Logroño, Spain.
A HurtadoMedical Oncology Department, Hospital Universitario Fundación Alcorcón, Madrid, Spain.
P CerdàMedical Oncology Department, Centro Médico Tecknon, Barcelona, Spain.
M GarridoMedical Oncology Department, Pontificia Universidad Católica de Chile, Santiago de Chile, Chile.
R Sánchez-BayonasMedical Oncology Department, Clínica Universidad de Navarra, Pamplona, Spain.
R SerranoMedical Oncology Department, Hospital Universitario Reina Sofía, Córdoba, Spain.
P Jiménez-FonsecaMedical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain.
AGAMENON Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe optimal duration of first-line chemotherapy for patients with advanced gastric cancer is unknown. Diverse clinical trials have proposed different strategies including limited treatment, maintenance of some drugs, or treatment until progression.

methodThe sample comprises patients from the AGAMENON multicenter registry without progression after second evaluation of response. The objective was to explore the optimal duration of first-line chemotherapy. A frailty multi-state model was conducted.

results415 patients were divided into three strata: discontinuation of platinum and maintenance with fluoropyrimidine until progression (30%, n = 123), complete treatment withdrawal prior to progression (52%, n = 216), and full treatment until progression (18%, n = 76). The hazard of tumor progression decreased by 19% per month with the full treatment regimen. However, we found no evidence that fluoropyrimidine maintenance (hazard ratio [HR] 1.07, confidence interval [CI] 95%, 0.69-1.65) worsened progression-free survival (PFS) with respect to treatment until progression. Predictive factors for PFS were ECOG performance status, ≥ 3 metastatic sites, prior tumor response, and bone metastases. Toxicity grade 3/4 was more common in those who continued the full treatment until progression vs fluoropyrimidine maintenance (16% vs 6%).

conclusionThe longer duration of the full initial regimen exerted a protective effect on the patients of this registry. Platinum discontinuation followed by fluoropyrimidine maintenance yields comparable efficacy to treatment up to PD, with a lower rate of serious adverse events.

Indexed as

RegistriesAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsClinical Decision-MakingFemaleHumansMaintenance ChemotherapyMaleMiddle AgedPlatinumProgression-Free SurvivalPyrimidinesStomach NeoplasmsSurvival RatePlatinumPyrimidinesAdvanced gastric cancerAGAMENONMaintenanceMulti-stateTreatment duration

Identifiers

PMID31385226

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.